Vaccibody AS (Euronext Growth Oslo: VACC)

https://www.vaccibody.com

LinkedIn: https://linkedin.com/company/vaccibody

Vaccibody is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies. The Company is using the Vaccibody technology platform to generate best-in-class therapeutics against cancers and infectious diseases with a high unmet medical need. Vaccibody is developing cutting-edge, targeted DNA vaccines for clinical use, based on a deep understanding of immunological principles. Vaccibody’s vaccines specifically target Antigen Presenting Cells (APC), which are essential for inducing rapid, strong and specific immune responses and elicit efficacious clinical responses. By intelligent design, Vaccibody’s vaccines can be tailored to induce the desired immune response profile correlating with protection for each specific disease with any given antigen. Hence, the Vaccibody vaccine platform has the potential to address many disease areas with a high unmet medical need such as cancer and infectious diseases. In addition, Vaccibody has collaborations with Roche and Nektar Therapeutics. Vaccibody’s shares are traded on NOTC, a marketplace for unlisted shares managed by NOTC AS, which is owned 100% by Oslo Børs ASA, the Oslo Stock Exchange. *

	Start	2012-08-13 existent
	End	2021-11-30 renamed
	Today	Nykode Therapeutics AS (Euronext Growth Oslo: NYKD)
	Successor	Nykode Therapeutics AS (Euronext Growth Oslo: NYKD)
	Industry	vaccine technology
	Industry 2	cancer vaccine

	Street	21 Gaustadalléen Oslo Research Park
	City	0349 Oslo
	Tel	+47-22-958193
		Address record changed: 2021-11-23

Basic data	Employees	n. a.

		* Document for »About Section«: Vaccibody AS. (10/1/20). "Press Release: Vaccibody Enters into Worldwide License and Collaboration Agreement with Genentech, a Member of the Roche Group, to Develop Individualized Neoantigen Cancer Vaccines". Oslo.

		Record changed: 2024-02-12

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for Vaccibody AS (Euronext Growth Oslo: VACC)

[1] Novo Holdings A/S. (11/26/19). "Press Release: Novo Seeds Expands Company Formation Activities at BiOrigin with Seasoned Entrepreneurs". Copenhagen....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)